The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Oral contraceptives containing drospirenone for premenstrual syndrome
Abstract
BACKGROUND: Premenstrual syndrome (PMS) is a common problem. Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome. Combined oral contraceptives, which provide both progestin and estrogen, have been examined for their ability to relieve premenstrual symptoms. An oral contraceptive containing drospirenone and a low estrogen dose has been approved for treating PMDD in women who choose oral contraceptives for contraception. OBJECTIVES: To review all randomized controlled trials comparing a combined oral contraceptive containing drospirenone to a placebo or another combined oral contraceptive for effect on premenstrual symptoms. SEARCH METHODS: We searched for studies of drospirenone and premenstrual syndrome in the following databases: Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, and POPLINE (20 Dec 2011); EMBASE, LILACS, PsycINFO, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) of the World Health Organization (02 Mar 2011). We also examined references lists of relevant articles and wrote to known investigators to find other trials. SELECTION CRITERIA: We included randomized controlled trials in any language that compared a combined oral contraceptive (COC) containing drospirenone with a placebo or with another COC for effect on premenstrual symptoms. The primary outcome included affective and physical premenstrual symptoms that were prospectively recorded. Adverse events related to combined oral contraceptive use were examined. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and assessed study quality. For continuous variables, the mean difference (MD) was computed with 95% confidence interval (CI). For dichotomous outcomes, the Peto odds ratio (OR) with 95% CI was calculated. MAIN RESULTS: We included five trials with a total of 1920 women. Two placebo-controlled trials of women with PMDD showed less severe premenstrual symptoms after three months with drospirenone 3 mg plus ethinyl estradiol 20 μg than with placebo (MD -7.92; 95% CI -11.16 to -4.67). The drospirenone group had greater mean decreases in impairment of productivity (MD -0.31; 95% CI -0.55 to -0.08), social activities (MD -0.29; 95% CI -0.54 to -0.04), and relationships (MD -0.30; 95% CI -0.54 to -0.06). Side effects more common with the use of the drospirenone COC contraceptive were nausea, intermenstrual bleeding, and breast pain. The respective odds ratios were 3.15 (95% CI 1.90 to 5.22), 4.92 (95% CI 3.03 to 7.96), and 2.67 (95% CI 1.50 to 4.78). Total adverse events related to the study drug were more likely for the drospirenone COC group (OR 2.36; 95% CI 1.62 to 3.44). Three trials studied the effect of drospirenone 3 mg plus ethinyl estradiol 30 μg on less severe symptoms. A placebo-controlled six-month trial had insufficient data for primary outcome analysis. Another six-month study used levonorgestrel 150 µg plus ethinyl estradiol 30 µg for the comparison group but did not provide enough data on premenstrual symptoms. In a two-year trial, the drospirenone COC group had similar premenstrual symptoms to the comparison group given desogestrel 150 µg plus ethinyl estradiol 30 µg (OR 0.87; 95% CI 0.63 to 1.22). The groups were also similar for adverse events related to treatment (OR 1.02; 95% CI 0.78 to 1.33). AUTHORS' CONCLUSIONS: Drospirenone 3 mg plus ethinyl estradiol 20 μg may help treat premenstrual symptoms in women with severe symptoms, that is, premenstrual dysphoric disorder. The placebo also had a large effect. We do not know whether the combined oral contraceptive works after three cycles, helps women with less severe symptoms, or is better than other oral contraceptives. Larger and longer trials of higher quality are needed to address these issues. Trials should follow CONSORT guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,175
Evidence-Based Medicine: How to Practice and Teach EBM
Sackett, D. L. (2000) · Cited by 5,950
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,401
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
(1993) · PubMed · Cited by 1,900
Evidence-based medicine : how to practice and teach EBM
Straus, S. E. (2005) · Cited by 1,367
Allocation concealment in randomised trials: defending against deciphering
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07750-4 · Cited by 923
The Development of a Menstrual Distress Questionnaire
MOOS, R. H. (1968) · Psychosomatic Medicine · doi:10.1097/00006842-196811000-00006 · Cited by 880
Schmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801223380401 · Cited by 765
Als-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746
Sample size slippages in randomised trials: exclusions and the lost and wayward.
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07882-0 · Cited by 642
Daily Record of Severity of Problems (DRSP): reliability and validity
Endicott, J., Nee, J., & Harrison, W. (2006) · Archives of Women's Mental Health · doi:10.1007/s00737-005-0103-y · Cited by 478
New progestagens for contraceptive use
Sitruk-Ware, R. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi046 · Cited by 362
Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
Yonkers, K. A., Brown, C., Pearlstein, T. B., Foegh, M., Sampson-Landers, C., & Rapkin, A. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000175834.77215.2e · Cited by 349
Greene, R., & Dalton, K. (1953) · BMJ · doi:10.1136/bmj.1.4818.1007 · Cited by 314
Pearlstein, T. B., Bachmann, G. A., Zacur, H. A., & Yonkers, K. A. (2005) · Contraception · doi:10.1016/j.contraception.2005.08.021 · Cited by 279
Mortola, J., Girton, L., Beck, L., & Yen, S. (1991) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(91)90644-k · Cited by 221
Preboth, M. (2000) · PubMed · Cited by 218
Practice Bulletin No. 110: Noncontraceptive Uses of Hormonal Contraceptives
(2010) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181cb50b5 · Cited by 208
Cognitive therapy for premenstrual syndrome
Blake, F., Salkovskis, P., Gath, D., Day, A., & Garrod, A. (1998) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(98)00042-7 · Cited by 196
Combination contraceptives: effects on weight
Gallo, M. F., Lopez, L. M., Grimes, D. A., Schulz, K. F., & Helmerhorst, F. M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003987.pub3 · Cited by 196
Self-citationA review of treatment of premenstrual syndrome & premenstrual dysphoric disorder
Rapkin, A. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(03)00096-9 · Cited by 176
Effect Measures for Meta‒Analysis of Trials with Binary Outcomes
Deeks, J. J., & Altman, D. G. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch16 · Cited by 170
Evaluation of a Unique Oral Contraceptive in the Treatment of Premenstrual Dysphoric Disorder
Freeman, E. W., Kroll, R., Rapkin, A., Pearlstein, T., Brown, C., Parsey, K., Zhang, P., Patel, H., & Foegh, M. (2001) · Journal of Women's Health & Gender-Based Medicine · doi:10.1089/15246090152543148 · Cited by 163
Johnson, S. R. (2004) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000140686.66212.1e · Cited by 153
Parsey, K., & Pong, A. (2000) · Contraception · doi:10.1016/s0010-7824(00)00083-4 · Cited by 149
TREATMENT OF PREMENSTRUAL SYNDROME BY SPIRONOLACTONE
O’Brien, P. M. S., CRAVEN, D. J., Selby, C., & SYMONDS, E. M. (1979) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1979.tb10582.x · Cited by 147
Hunter, M. S., Ussher, J. M., Browne, S. J., Cariss, M., Jelley, R., & Katz, M. (2002) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.3109/01674820209074672 · Cited by 128
Prevalence of sexual abuse history in a sample of women seeking treatment for premenstrual syndrome
Golding, J. M., Taylor, D. L., Menard, L., & King, M. (2000) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.3109/01674820009075612 · Cited by 128
Treatment of premenstrual syndrome by spironolactone: A double‐blind, placebo‐controlled study
Wang, M., Hammarbäck, S., Lindhe, B., & Bäckström, T. C. (1995) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016349509021201 · Cited by 121
Foidart, J. M., Wuttke, W., Gm, B., Gerlinger, C., & Heithecker, R. (2000) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625180008500387 · Cited by 121
Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee, A. L., Kuehl, T., Willis, S., & Sulak, P. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.05.012 · Cited by 118
Drospirenone, a progestogen with antimineralocorticoid properties: a short review
Oelkers, W. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.030 · Cited by 98
Apter, D. L., Borsos, A., Baumgärtner, W., Melis, G. B., Vexiau-Robert, D., Colligs-Hakert, A., PALMER, M. A., & Kelly, S. (2003) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/ejc.8.1.37.51 · Cited by 79
Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model
Kurshan, N., & Epperson, C. N. (2005) · Archives of Women s Mental Health · doi:10.1007/s00737-005-0102-z · Cited by 75
Assessing the assessment measures for menstrual cycle symptoms
Haywood, A., Slade, P., & King, H. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00297-0 · Cited by 73
Kelly, S., Davies, E., Fearns, S., McKinnon, C., Carter, R., Gerlinger, C., & Smithers, A. (2010) · Clinical Drug Investigation · doi:10.2165/11535450-000000000-00000 · Cited by 73
Progesterone for premenstrual syndrome
Ford, O., Lethaby, A. E., Roberts, H., & Mol, B. W. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003415.pub3 · Cited by 73
Sangthawan, M., & Taneepanichskul, S. (2005) · Contraception · doi:10.1016/j.contraception.2004.07.010 · Cited by 70
ICH E9 guideline ‘Statistical principles for clinical trials’: a case study
Phillips, A., & Haudiquet, V. (2002) · Statistics in Medicine · doi:10.1002/sim.1328 · Cited by 58
Joffe, H., Petrillo, L. F., Viguera, A. C., Gottshcall, H., Soares, C. N., Hall, J. E., & Cohen, L. S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1218 · Cited by 55
Paoletti, A. M., Lello, S., Fratta, S., Orrù, M., Ranuzzi, F., Sogliano, C., Concas, A., Biggio, G., & Melis, G. B. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.08.030 · Cited by 53
Gallo, M. F., Nanda, K., Grimes, D. A., & Schulz, K. F. (2005) · Contraception · doi:10.1016/j.contraception.2004.09.005 · Cited by 47
Therapeutic management of premenstrual syndrome
Freeman, E. W. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.509344 · Cited by 46
Premenstrual syndrome: an update on definitions, diagnosis and management
Connolly, M. (2001) · Advances in Psychiatric Treatment · doi:10.1192/apt.7.6.469 · Cited by 44
Machado, R. B., de Melo, N. R., & Maia, H. (2009) · Contraception · doi:10.1016/j.contraception.2009.10.010 · Cited by 42
Added benefits of drospirenone for compliance
Foidart, J. M. (2005) · Climacteric · doi:10.1080/13697130500330309 · Cited by 41
Ross, C., Coleman, G. J., & Stojanovska, C. (2003) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.3109/01674820309039670 · Cited by 39
Machado, R. B., de Melo, N. R., Maia, H., & Cruz, A. M. (2009) · Contraception · doi:10.1016/j.contraception.2009.08.009 · Cited by 38
Haywood, A., Slade, P., & King, H. (2006) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2006.07.024 · Cited by 37
Marr, J., Niknian, M., SHULMAN, L. P., & Lynen, R. (2010) · Contraception · doi:10.1016/j.contraception.2010.10.010 · Cited by 37
Combination contraceptives: effects on weight
Gallo, M. F., Grimes, D. A., Schulz, K. F., & Helmerhorst, F. M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003987 · Cited by 37
Self-citationBorges, L. E., de Andrade, R. P., Aldrighi, J. M., Guazelli, C., Yazlle, M. E. H. D., Isaia, C. F. P., Petracco, Á., Peixoto, F. C., & Camargos, A. F. (2006) · Contraception · doi:10.1016/j.contraception.2005.10.016 · Cited by 26
Premenstrual disorders: prevalence, etiology and impact.
Winer, S. A., & Rapkin, A. J. (2006) · PubMed · Cited by 22
Marr, J., Heinemann, K., Kunz, M., & Rapkin, A. J. (2011) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2010.10.029 · Cited by 20
Fan, G.-S., Bian, M., Li-Nan, C., Cao, X., Huang, Z., Zi-Yan, H., Xiao-Ping, J., Li, J., Shuying, W., Chengliang, X., et al. (2010) · Clinical Drug Investigation · doi:10.1007/bf03256908 · Cited by 18
Braverman, P. K., & Breech, L. L. (2009) · International Journal of Women s Health · doi:10.2147/ijwh.s4338 · Cited by 11
Fan, G.-S., Bian, M., Cheng, L., et al. (2009) · PubMed · Cited by 4
Cited by
van Hylckama Vlieg, A., Helmerhorst, F. M., Vandenbroucke, J. P., Doggen, C. J. M., & Rosendaal, F. R. (2009) · BMJ · doi:10.1136/bmj.b2921 · Cited by 666
Self-citationSelective serotonin reuptake inhibitors for premenstrual syndrome
Marjoribanks, J., Brown, J., O'Brien, P. M. S., & Wyatt, K. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001396.pub3 · Cited by 413
Premenstrual Dysphoric Disorder: Epidemiology and Treatment
Hantsoo, L., & Epperson, C. N. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0628-3 · Cited by 329
Yonkers, K. A., & Simoni, M. K. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.05.045 · Cited by 323
ISPMD consensus on the management of premenstrual disorders
Consensus Group of the International Society for Premenstrual Disorders, Nevatte, T., O’Brien, P. M. S., Bäckström, T., Brown, C., Dennerstein, L., Endicott, J., Epperson, C. N., Eriksson, E., Freeman, E. W., et al. (2013) · Archives of Women s Mental Health · doi:10.1007/s00737-013-0346-y · Cited by 211
Metadata
- Authors
- Lopez, L. M., Kaptein, A. A., & Helmerhorst, F. M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-02-15
- Issue
- 2
- Pages
- CD006586-CD006586
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2120463030
- Cited by
- 270
- References
- 61
- FWCI
- 16.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.